Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Long-Term Deferred Tax (2016 - 2019)

Harvard Bioscience (HBIO) has disclosed Long-Term Deferred Tax for 10 consecutive years, with $210000.0 as the latest value for Q2 2019.

  • On a quarterly basis, Long-Term Deferred Tax rose 18.64% to $210000.0 in Q2 2019 year-over-year; TTM through Jun 2019 was $210000.0, a 18.64% increase, with the full-year FY2017 number at $182000.0, down 84.27% from a year prior.
  • Long-Term Deferred Tax was $210000.0 for Q2 2019 at Harvard Bioscience, up from $208000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $11.0 million in Q3 2015 to a low of $177000.0 in Q2 2018.
  • A 5-year average of $2.6 million and a median of $1.0 million in 2016 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: tumbled 91.57% in 2016, then skyrocketed 36.73% in 2017.
  • Harvard Bioscience's Long-Term Deferred Tax stood at $995000.0 in 2015, then increased by 16.28% to $1.2 million in 2016, then plummeted by 84.27% to $182000.0 in 2017, then fell by 1.65% to $179000.0 in 2018, then grew by 17.32% to $210000.0 in 2019.
  • Per Business Quant, the three most recent readings for HBIO's Long-Term Deferred Tax are $210000.0 (Q2 2019), $208000.0 (Q1 2019), and $179000.0 (Q3 2018).